The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Open accessAbstract
We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway. In ovarian cancer (OC), DNMTis trigger cytosolic sensing of double-stranded RNA (dsRNA) causing a type I interferon response and apoptosis. Knocking down dsRNA sensors TLR3 and MAVS reduces this response 2-fold and blocking interferon beta or its receptor abrogates it. Upregulation of hypermethylated endogenous retrovirus (ERV) genes accompanies the response and ERV overexpression activates the response. Basal levels of ERV and viral defense gene expression significantly correlate in primary OC and the latter signature separates primary samples for multiple tumor types from The Cancer Genome Atlas into low versus high expression groups. In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The IFN-I response could also expose the tumor cells to surveillance by the immune system96, 97.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [97]
The cited source says what the claim attributes to it.
In the citing paper
“multiple studies have shown that DNA demethylating agents among other epigenetic modulators can induce a type I IFN response in cancer cells through the de-repression of endogenous retroviruses (ERVs) and activation of the MDA5-MAVS pathway38–40.”
From Epigenetic state determines the in vivo efficacy of STING agonist therapy (2023) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“DAC treatment could induce expression of retrotransposons normally silenced by DNA methylation, which could also augment tumor immunogenicity10–14,99.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“inactivated typical enhancers were associated with collagen fibril organization and chemotaxis GO terms and were enriched for binding motifs of immune-related TFs, including STAT1 (Fig. 2a, b)12,13.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“inhibiting EZH2 activity can either positively or negatively influence tumour-specific immune responses by modulating both tumour immunogenicity and the function of infiltrating T-cells, NK-cells and macrophages 196 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [196]
In the citing paper
“derepression of endogenous retroviral elements coupled to robust type I and type III IFN signaling”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chiappinelli et al., 2015
In the citing paper
“Certainly, this dual epigenetic targeting may influence additional antiproliferative mechanisms and further enhance antitumor surveillance by the immune system (Chiappinelli et al., 2015).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Chiappinelli et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,645
Flagged first, then by citations
1 of the 94 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 901–1,000 of 1,003
Azoximer Bromide: Mystery, Serendipity, and Promise
Grivtsova, L. Y., Falaleeva, N. A., & Tupitsyn, N. N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.699546 · Cited by 20
Lee, H. M., Saw, A. K., Morris, V. K., Napolitano, S., Bristow, C. A., Srinivasan, S., Peoples, M. D., Sorokin, A. V., Marie, P. K., Schulz, J. E., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1166 · Cited by 21
Huang, C., Gao, Y., Chen, J., Hong, J. H., Jiang, Y., Chai, K. X. Y., Li, Y., Wang, P., Wang, Y., Gao, J., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0587 · Cited by 23
Chen, D., Wen, X., Song, Y. S., Rhee, Y.-Y., Lee, T. H., Cho, N., Han, S., Kim, T., & Kang, G. H. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0203-8 · Cited by 20
The added value of type I interferons to cytotoxic treatments of cancer
Bracci, L., Sistigu, A., Proietti, E., & Moschella, F. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.008 · Cited by 20
Maćkowska‐Maślak, N., Drobna‐Śledzińska, M., Witt, M., & Dawidowska, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031388 · Cited by 21
Oncolytic Virotherapy: The Cancer Cell Side
Ehrlich, M., & Bacharach, E. (2021) · Cancers · doi:10.3390/cancers13050939 · Cited by 23
Harms, P. W., Verhaegen, M. E., Vo, J. N., Tien, J. C.-Y., Pratt, D. W., Su, F., Dhanasekaran, S. M., Cao, X., Mangelberger, D., Goor, J. J. V., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.07.173 · Cited by 20
Latifi, T., Zebardast, A., & Marashi, S. M. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103318 · Cited by 20
Wong‐Brown, M. W., van der Westhuizen, A., & Bowden, N. A. (2022) · BMC Cancer · doi:10.1186/s12885-022-09197-w · Cited by 20
Recurrent transcriptional responses in AML and MDS patients treated with decitabine
Upadhyay, P., Beales, J. T., Shah, N. M., Gruszczyńska, A., Miller, C. A., Petti, A. A., Ramakrishnan, S. M., Link, D. C., Ley, T. J., & Welch, J. S. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.04.002 · Cited by 20
Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer
Shin, D. S., Park, K., Garon, E. B., & Dubinett, S. M. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.06.005 · Cited by 20
The lncRNA ALPHA specifically targets chikungunya virus to control infection
Basavappa, M. G., Ferretti, M., Dittmar, M., Stoute, J., Sullivan, M. C., Whig, K., Shen, H., Liu, K. F., Schultz, D., Beiting, D. P., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.08.030 · Cited by 21
Traynor, S., Terp, M. G., Nielsen, A., Guldberg, P., Jakobsen, M. K., Pedersen, P. G., Gammelgaard, O. L., Pedersen, C. B., Pedersen, M., Rattenborg, S., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215982 · Cited by 22
Activation of cytosolic RNA sensors by endogenous ligands: roles in disease pathogenesis
Straub, S., & Sampaio, N. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1092790 · Cited by 21
Chen, Z., Yin, M., Jia, H., Chen, Q., & Zhang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1176103 · Cited by 20
Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment
Chaudhri, A., Lizee, G. A., Hwu, P., & Rai, K. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2244 · Cited by 21
Usart, M., Stetka, J., Paz, D. L., Hansen, N., Kimmerlin, Q., Fonseca, T. A., Lock, M., Kubovčáková, L., Karjalainen, R., Hao-Shen, H., et al. (2024) · Blood · doi:10.1182/blood.2023020270 · Cited by 22
Tang, J., Pulliam, N., Özeş, A., Buechlein, A. M., Ding, N., Keer, H. N., Rusch, D. B., O’Hagan, H. M., Stack, M. S., & Nephew, K. P. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0406 · Cited by 20
Activation of viral defense signaling in cancer
González‐Cao, M., Karachaliou, N., Santarpía, M., Viteri, S., Meyerhans, A., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918793105 · Cited by 21
Wylie, B., Chee, J., Forbes, C. A., Booth, M. W., Stone, S. R., Buzzai, A. C., Abad, A., Foley, B. A., Cruickshank, M. N., & Waithman, J. C. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1609874 · Cited by 20
DNA methyltransferase inhibition reduces inflammation-induced colon tumorigenesis
Maiuri, A. R., Savant, S. S., Podicheti, R., Rusch, D. B., & O’Hagan, H. M. (2019) · Epigenetics · doi:10.1080/15592294.2019.1634986 · Cited by 21
Hussein, S. E., Shaw, K. R. M., & Vega, F. (2020) · Modern Pathology · doi:10.1038/s41379-020-0616-y · Cited by 20
Ahn, A., Rodger, E. J., Motwani, J., Gimenez, G., Stockwell, P. A., Parry, M. F., Hersey, P., Chatterjee, A., & Eccles, M. R. (2021) · Cancers · doi:10.3390/cancers13174250 · Cited by 21
Trovato, M., Bunina, D., Yildiz, U., Marx, N. F.-N., Uckelmann, M., Levina, V., Perez, Y., Janeva, A., Garcia, B. A., Davidovich, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51785-w · Cited by 20
LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma
You, E., Patel, B. K., Rojas, A. S., Sun, S., Danaher, P. J., Ho, N. I., Phillips, I. E., Raabe, M. J., Song, Y., Xu, K. H., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1317 · Cited by 20
The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes
Chokr, N., Patel, R. D., Wattamwar, K., & Chokr, S. (2018) · Advances in Hematology · doi:10.1155/2018/2458679 · Cited by 19
Hurst, T. P., Aswad, A., Karamitros, T., Katzourakis, A., Smith, A. L., & Magiorkinis, G. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01426 · Cited by 20
Rewiring of chromatin state and gene expression by transposable elements
Ohtani, H., & Iwasaki, Y. W. (2021) · Development Growth & Differentiation · doi:10.1111/dgd.12735 · Cited by 23
Sheikh, T. N., Chen, X., Xu, X., McGuire, J. T., Ingham, M. A., Lü, C., & Schwartz, G. K. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0066 · Cited by 19
EZH2 suppresses endogenous retroviruses and an interferon response in cancers
Jayabal, P., Ma, X., & Shiio, Y. (2021) · Genes & Cancer · doi:10.18632/genesandcancer.218 · Cited by 19
Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer
Alizadeh‐Ghodsi, M., Owen, K. L., Townley, S. L., Zanker, D. J., Rollin, S., Hanson, A. R., Shrestha, R. K., Toubia, J., Gargett, T., Chernukhin, I. V., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0139 · Cited by 19
Inhibiting DNA methylation improves antitumor immunity in ovarian cancer
Chiappinelli, K. B., & Baylin, S. B. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160186 · Cited by 19
Self-citationLiu, H., Bergant, V., Frishman, G., Ruepp, A., Pichlmair, A., Vincendeau, M., & Frishman, D. (2022) · Viruses · doi:10.3390/v14071591 · Cited by 20
Kang, S., Wang, L., Xu, L., Wang, R. L., Kang, Q., Gao, X., & Yu, L. (2022) · Oncogene · doi:10.1038/s41388-022-02455-y · Cited by 19
Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies
Rubanov, A., Berico, P., & Hernando, E. (2022) · Cancers · doi:10.3390/cancers14235858 · Cited by 23
DNA methylation in cell plasticity and malignant transformation in liver diseases
Kim, M., Delgado, E. R., & Ko, S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108334 · Cited by 20
RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma
Lambing, S., Tan, Y. P., Vasileiadou, P., Holdenrieder, S., Müller, P., Hagen, C., Garbe, S., Behrendt, R., Schlee, M., van den Boorn, J. G., et al. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad001 · Cited by 22
Lee, D. Y., Salahuddin, T., & Iqbal, J. (2023) · Current Oncology · doi:10.3390/curroncol30020164 · Cited by 19
RELA tunes innate-like interferon I/III responses in human T cells
Jeremiah, N., Ferran, H., Antoniadou, K., de Azevedo, K., Nikolić, J., Maurin, M., Benaroch, P., & Manel, N. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20220666 · Cited by 17
Exploring HERV-K (HML-2) Influence in Cancer and Prospects for Therapeutic Interventions
Costa, B., & Vale, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914631 · Cited by 20
GAS-STING: a classical DNA recognition pathways to tumor therapy
Wang, X., Lin, M., Zhu, L., & Ye, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1200245 · Cited by 22
Zheng, K. C., Hai, Y., Xi, Y., Zhang, Y., Liu, Z., Chen, W., Hu, X., Zou, X., & Hao, J. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04683-6 · Cited by 19
Transcription of Endogenous Retroviruses: Broad and Precise Mechanisms of Control
Jarosz, A. S., & Halo, J. V. (2024) · Viruses · doi:10.3390/v16081312 · Cited by 20
Truong, P., Shen, S., Joshi, S. M., Islam, M. I., Zhong, L., Raftery, M. J., Afrasiabi, A., Alinejad-Rokny, H., Nguyen, M. T. H. D., Zou, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51646-6 · Cited by 19
Epigenetic control of immunoevasion in cancer stem cells
Galassi, C., Esteller, M., Vitale, I., & Galluzzi, L. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.08.004 · Cited by 20
Dying to survive: harnessing inflammatory cell death for better immunotherapy
Cheng, L., Wang, Y., & Zhang, Y. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.01.012 · Cited by 19
Fueling Type I Interferonopathies: Regulation and Function of Type I Interferon Antiviral Responses
Ng, C. S., Kato, H., & Fujita, T. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2019.0037 · Cited by 19
Saito, Y. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14773 · Cited by 19
Gassenmaier, M., Rentschler, M., Fehrenbacher, B., Eigentler, T., Ikenberg, K., Kosnopfel, C., Sinnberg, T. W., Niessner, H., Bösmüller, H. C., Wagner, N. B., et al. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.07.002 · Cited by 20
Declerck, K., Perez-Novo, C. A., Grielens, L., Camp, G. V., Suter, A., & Berghe, W. V. (2021) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-021-03310-5 · Cited by 20
Exosomes transmit retroelement RNAs to drive inflammation and immunosuppression in Ewing SarcomaPreprint
Evdokimova, V. E., Ruzanov, P., Gassmann, H., Zaidi, S. H. E., Peltekova, V. D., Heisler, L. E., McPherson, J. D., Orlic-Milacic, M., Specht, K., Steiger, K., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/806851 · Cited by 19
Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
McGeary, M. K., Damsky, W., Daniels, A. J., Lang, S. M., Xu, Q., Song, E., Huet-Calderwood, C., Lou, H. J., Paradkar, S., Micevic, G., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0514 · Cited by 19
Defining ortholog-specific UHRF1 inhibition by STELLA for cancer therapy
Bai, W., Xu, J., Gu, W., Wang, D., Cui, Y., Rong, W., Du, X., Li, M., Xia, C., Gan, Q., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55481-7 · Cited by 20
Self-citationSharma, D., Dhiman, I., Paul, S. D., Das, D. K., Das, D., Dash, S. K., & Pramanik, A. (2025) · ACS Omega · doi:10.1021/acsomega.5c02077 · Cited by 18
The nuclear periphery confers repression on H3K9me2-marked genes and transposons to shape cell fate
Marin, H. C., Allen, C., Simental, E., Martin, E. W., Panning, B., Al‐Sady, B., & Buchwalter, A. L. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01703-z · Cited by 20
Vito, A. D., Lazzaro, M., Palmisano, I., Cittaro, D., Riba, M., Lazarevic, D., Bannai, M., Gabellini, D., & Schiaffino, M. V. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200783 · Cited by 16
Onishi‐Seebacher, M., Erikson, G. A., Sawitzki, Z., Ryan, D., Greve, G., Lübbert, M., & Jenuwein, T. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-01003-z · Cited by 19
Koenig, M. J., Agana, B. A., Kaufman, J. M., Sharpnack, M. F., Wang, W. Z., Weigel, C., Navarro, F. C. P., Amann, J. M., Cacciato, N., Arasada, R. R., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3199 · Cited by 18
A Dual Role of DDX3X in dsRNA-Derived Innate Immune Signaling
Kwon, J., Choi, H., & Han, C. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.912727 · Cited by 19
All Quiet on the TE Front? The Role of Chromatin in Transposable Element Silencing
Di Stefano, L. (2022) · Cells · doi:10.3390/cells11162501 · Cited by 18
Bonté, P., Metoikidou, C., Heurtebise-Chrétien, S., Arribas, Y. A., Galy, A. S. D., Ye, M., Niborski, L. L., Zueva, E., Piaggio, E., Seguin‐Givelet, A., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adf8838 · Cited by 19
Retrotransposon life cycle and its impacts on cellular responses
Luqman-Fatah, A., Nishimori, K., Amano, S., Fumoto, Y., & Miyoshi, T. (2024) · RNA Biology · doi:10.1080/15476286.2024.2409607 · Cited by 20
Solovyov, A., Behr, J. M., Hoyos, D., Banks, E., Drong, A., Thornlow, B. P., Zhong, J. Z., Garcia-Rivera, E., McKerrow, W., Chu, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57271-1 · Cited by 20
Liu, L., Chen, L., Wu, X., Li, X., Song, Y., Mei, Q., Nie, J., & Han, W. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2157-9 · Cited by 18
Vougiouklakis, T., Bao, R., Nakamura, Y., & Saloura, V. (2017) · Oncotarget · doi:10.18632/oncotarget.22627 · Cited by 16
Schcolnik‐Cabrera, A., Domínguez-Gómez, G., & Dueñas‐González, A. (2018) · Europe PMC (PubMed Central) · Cited by 18
Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers
Segovia, M., Russo, S., Girotti, M. R., Rabinovich, G. A., & Hill, M. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13433 · Cited by 17
Gregório, C., Soares‐Lima, S. C., Alemar, B., Recamonde‐Mendoza, M., Camuzi, D., de Souza-Santos, P. T., Rivero, R. C., Machado, S. M. D. S., Osvaldt, A. B., Ashton‐Prolla, P., et al. (2020) · Cancers · doi:10.3390/cancers12071735 · Cited by 19
Hargadon, K. M. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20608 · Cited by 18
Boosting Antitumor Immunity with an Expanded Neoepitope Landscape
Nagel, R., Pataskar, A., Champagne, J., & Agami, R. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1525 · Cited by 21
Andrade, A. F., Borges, K. S., Suazo, V. K., Geron, L., Corrêa, C. A. P., Castro‐Gamero, A. M., Vasconcelos, E. J. R., de Oliveira, R. S., Neder, L., Yunes, J. A., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0412-1 · Cited by 18
Haffner, M. C., Taheri, D., Imada, E. L., Palsgrove, D. N., Eich, M., Netto, G. J., Matoso, A., Nirschl, T. R., Zheng, Q., Hicks, J. L., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803292115 · Cited by 18
Lai, T. J., Sun, L., Li, K., Prins, T. J., Treger, J. M., Li, T., Sun, M. Z., Nathanson, D. A., Liau, L. M., Lai, A., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0566 · Cited by 17
Leveraging genetics to understand ADAR1-mediated RNA editing in health and disease
Li, J. B., & Walkley, C. R. (2025) · Nature Reviews Genetics · doi:10.1038/s41576-025-00830-5 · Cited by 22
Epigenetic Therapies in Melanoma—Targeting DNA Methylation and Histone Modification
Țigu, A. B., Ivancuta, A., Uhl, A., Sabo, A. C., Nistor, M., Mureșan, X. M., Cenariu, D., Timis, T., Diculescu, D. M., & Gulei, D. (2025) · Biomedicines · doi:10.3390/biomedicines13051188 · Cited by 17
Zhu, D., Li, Z., Feng, H., Zheng, J., Xiao, X., Huang, Z., Zheng, L., Guo, J., Ling, F., Li, Y., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011650 · Cited by 19
DNA methylation protects cancer cells against senescence
Chen, X., Yamaguchi, K., Rodgers, B., Goehrig, D., Vindrieux, D., Lahaye, X., Nolot, M., Ferry, L., Lanciano, S., Martin, N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61157-7 · Cited by 17
Lewis, R. T., Sinigiani, V., Maziak, N., Koós, K., Bersaglieri, C., Zemp, I., Ashiono, C., Ciaudo, C., Horváth, P., Vaquerizas, J. M., et al. (2026) · Nature Cell Biology · doi:10.1038/s41556-025-01822-7 · Cited by 22
Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation
Fayyad‐Kazan, M., Al-Tameemi, S. A., & Ouhtit, A. (2026) · Cells · doi:10.3390/cells15050393 · Cited by 17
Gosu, V., Sasidharan, S., Saudagar, P., Lee, H., & Shin, D. (2021) · Biomolecules · doi:10.3390/biom11081251 · Cited by 17
Human LINE-1 retrotransposons: impacts on the genome and regulation by host factors
Luqman-Fatah, A., & Miyoshi, T. (2022) · Genes & Genetic Systems · doi:10.1266/ggs.22-00038 · Cited by 20
Alldredge, J. K., Kumar, V., Nguyen, J., Sanders, B. E., Gomez, K. E., Jayachandran, K., Zhang, J., Schwarz, J. K., & Rahmatpanah, F. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021492 · Cited by 17
Non-Small Cell Lung Cancer Epigenomes Exhibit Altered DNA Methylation in Smokers and Never-Smokers
Karlow, J. A., Pehrsson, E. C., Xing, X., Watson, M. A., Devarakonda, S. H. K., Govindan, R., & Wang, T. (2023) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2023.03.006 · Cited by 18
Jia, M., Chai, L., Wang, J., Wang, M., Qin, D., Song, H., Fu, Y., Zhao, C., Gao, C., Jia, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46212-z · Cited by 18
Epigenetic Therapies in Triple-Negative Breast Cancer: Concepts, Visions, and Challenges
Lehmann, U. (2024) · Cancers · doi:10.3390/cancers16122164 · Cited by 17
Compartmentation of Metabolites in Regulating Epigenomes of Cancer
Zhao, Z., Wang, L., & Di, L. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00051 · Cited by 18
Enigma of Retrotransposon Biology in Mammalian Early Embryos and Embryonic Stem Cells
Yin, Y., Zhou, L., & Yuan, S. (2018) · Stem Cells International · doi:10.1155/2018/6239245 · Cited by 18
Giovinazzo, A., Balestrieri, E., Petrone, V., Argaw-Denboba, A., Cipriani, C., Miele, M. T., Grelli, S., Vallebona, P. S., & Matteucci, C. (2019) · Cancer Microenvironment · doi:10.1007/s12307-019-00231-3 · Cited by 17
Human Endogenous Retroviruses as Biomedicine Markers
Song, Y., Li, X., Wei, X., & Cui, J. (2021) · Virologica Sinica · doi:10.1007/s12250-021-00387-7 · Cited by 17
Immunological Significance of Prognostic DNA Methylation Sites in Hepatocellular Carcinoma
Xu, Q., Hu, Y., Chen, S., Zhu, Y., Li, S., Shen, F., Guo, Y., Sun, T., Chen, X., Jiang, J., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.683240 · Cited by 17
Targeting protein kinases benefits cancer immunotherapy
Zhang, Z., Bu, L., Luo, J., & Guo, J. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188738 · Cited by 18
Impaired activation of transposable elements in SARS‐CoV‐2 infection
Sorek, M., Meshorer, E., & Schlesinger, S. (2022) · EMBO Reports · doi:10.15252/embr.202255101 · Cited by 17
Sylvestre, M., Tarte, K., & Roulois, D. (2019) · Epigenomics · doi:10.2217/epi-2019-0165 · Cited by 18
Competency-based training in SMES: the role of e-learning and e-competence
Hamburg, I., & Engert, S. (2007) · Cited by 17
Snowbarger, J. M., Koganti, P., & Spruck, C. (2024) · Biomolecules · doi:10.3390/biom14101250 · Cited by 14
RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications
Huang, S., Li, Z., Lin, W., Xie, R., & Huang, H. (2025) · MedComm · doi:10.1002/mco2.70322 · Cited by 19
Ran, J., Li, J., Yin, L., Zhang, D., Yu, C., Du, H., Jiang, X., Yang, C., & Liu, Y. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.697121 · Cited by 16
Bankova, A. K., Pang, W. W., Velasco, B. J., Long-Boyle, J. R., & Shizuru, J. A. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003841 · Cited by 16
Mutant KRAS regulates transposable element RNA and innate immunity via KRAB zinc-finger genes
Reggiardo, R. E., Maroli, S. V., Halasz, H., Ozen, M. O., Hrabeta‐Robinson, E., Behera, A. K., Peddu, V., Carrillo, D., LaMontagne, E., Whitehead, L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111104 · Cited by 24
Metadata
- Authors
- Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., Makarov, V., Buhu, S., Slamon, D. J., Wolchok, J. D., Pardoll, D. M., Beckmann, M. W., Zahnow, C. A., Merghoub, T., Chan, T. A., Baylin, S. B., & Strick, R.
- Affiliations
- Johns Hopkins University (US)
- Universitätsklinikum Erlangen (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Case Western Reserve University (US)
- University of California, Los Angeles (US)
- Corresponding author
- Baylin, Stephen B.
- Strick, Reiner
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 162
- Issue
- 5
- Pages
- 974-986
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4556003
- OpenAlex
- W1953890763
- Cited by
- 2,022
- References
- 94
- Citations by year
- 2026: 193 · 2025: 188 · 2024: 211 · 2023: 209 · 2022: 225 · 2021: 250 · 2020: 184 · 2019: 163 · 2018: 161 · 2017: 133 · 2016: 93 · 2015: 10
- FWCI
- 65.10
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA058184, CA058184, F32CA183214, P30CA008748)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- hypomethylating agents, DNA methylation, type I interferon response, double-stranded RNA sensing, endogenous retroviruses, ovarian cancer, melanoma, TLR3, MAVS, interferon-beta, apoptosis, immune checkpoint therapy, CTLA-4, tumor immune microenvironment, epigenetic reprogramming
- MeSH terms
- Animals, Azacitidine, Female, Humans, Immunotherapy, Interferon Type I, Lung Neoplasms, Melanoma, Mice, Inbred C57BL, Ovarian Neoplasms, RNA, Double-Stranded, DNA Modification Methylases, DNA Methylation, Endogenous Retroviruses, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
